1.
Full Text
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, ISSN 1554-8627, 01/2016, Volume 12, Issue 1, pp. 1 - 222
stress | chaperone-mediated autophagy | vacuole | autolysosome | macroautophagy | flux | autophagosome | LC3 | lysosome | phagophore | Phagophore | Lysosome | Autolysosome | Flux | Autophagosome | Vacuole | Chaperonemediated autophagy | Macroautophagy | Stress | ACTIVATED PROTEIN-KINASE | ENDOPLASMIC-RETICULUM STRESS | STARVATION-INDUCED AUTOPHAGY | GLUCAGON-INDUCED AUTOPHAGY | CELL BIOLOGY | PROGRAMMED CELL-DEATH | LIFE-SPAN EXTENSION | BETAINE HOMOCYSTEINE METHYLTRANSFERASE | VACUOLAR MEMBRANE DYNAMICS | NF-KAPPA-B | Autophagy - physiology | Biological Assay - methods | Animals | Biological Assay - standards | Computer Simulation | Humans | Life Sciences | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
Journal Article